Connect Biopharma Holdings Limited (CNTB) Upgraded to Overweight at Piper Sandler

Market Context

Connect Biopharma Holdings Limited operates in the Healthcare sector. The stock currently trades at $2.19 with a market capitalization of $136.4M.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Piper Sandler's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Connect Biopharma Holdings Limited

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 26, 2026	Piper Sandler	Overweight	N/A
Jun 25, 2026	HC Wainwright & Co.	Buy	N/A
May 26, 2026	Canaccord Genuity	Buy	N/A
May 21, 2026	Cantor Fitzgerald	Overweight	N/A
Apr 01, 2026	BTIG	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View CNTB Stock Page